Idiopathic Generalized Epilepsy Syndromes
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age4-40
SponsorShen Chun-Hong
About this trial
The idiopathic generalized epilepsies (IGEs) have historically included the syndromes childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizures alone (GTCA). Recognition of the IGEs is important for clinical care, as it informs diagnosis, prevents unnecessary investigation, allows optimal selection of anti-seizure medications (ASMs), and provides prognostic guidance.
According to the new ILAE definition in 2022, the study aims to describe the clinical features, electroencephalographic, imaging findings and long-term prognosis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients are consecutively and prospectively enrolled from epilepsy center, with newly diagnosed epilepsy or established epilepsy.
Patients have a diagnosis of idiopathic generalized epilepsy (IGE), according to the 2022 diagnostic criteria.
Comprehensive clinical information is collected, and 24 hour video-electroencephalography is performed.
Sign the informed consent forms.
Disqualifiers
Other epilepsy syndromes are considered during follow-up, such as genetic generalized epilepsy.
Lost to follow-up
Trial population
Patients are consecutively and prospectively recruited from epilepsy center and clinics
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
The proportion of drug-resistent epilepsy
We defined drug-resistant cases as those patients who have failed two or more trials of broad-spectrum ASMs or those otherwise indicated in IGE syndromes
Time frame
through study completion, an average of 1 year2
The proportion of seizure freedom
We defined seizure freedom according to the International League Against Epilepsy (ILAE) definition
Time frame
through study completion, an average of 1 yearSecondary outcomes
1
The proportion of psychiatric comorbidity
The psychiatric comorbidities mainly include anxiety and depression, which are evaluated by Hamilton anxiety scale and Hamilton depression scale, respectively.
Time frame
through study completion, an average of 1 year2
The proportion of psychosocial outcome
such as university entrance, marry
Time frame
through study completion, an average of 1 year3
The proportion of seizure relapse after antiseizure medication withdrawn
Antiseizure medication withdrawn should be recommended by epilepsy experts
Time frame
through study completion, an average of 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Shen Chun-Hong
Lead sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor institution
Source ClinicalTrials.gov